Commentary about treatment of male hypogonadism with clomiphene citrate compare to treatment with testosterone
Internal Medicine and Transitional Residency programs, Sunrise Health GME Consortium, Mountain View Hospital, Las Vegas, Nevada, USA.
Review Article
World Journal of Advanced Research and Reviews, 2022, 15(03), 256–260
Article DOI: 10.30574/wjarr.2022.15.3.0918
Publication history:
Received on 12 August 2022; revised on 18 September 2022; accepted on 20 September 2022
Abstract:
Clomiphene citrate (CC) is a selective estrogen receptor modulator and estrogen antagonist. It was introduced into clinical medicine in 1967 for the treatment of female infertility. CC has also been explored for off-label use for male infertility and male hypogonadal symptoms. We want to comment and discuss medical literature on CC and its contribution to the treatment of male hypogonadism. The main goal of the commentary is to discuss mechanism of action of CC and when it can be used for treatment of male hypogonadism instead of Testosterone which treatment is FDA approved. [1,2]. CC increases the Testosterone level in the blood similar to Testosterone gel. It improves the hypogonadal symptoms as well. The difference with CC and Testosterone is that CC preserves the sperm production and fertility if fertility is desired in patients with secondary/tertiary hypogonadism. The safety of CC was compared to Testosterone safety as well. CC is regarded as an effective therapy for specific patients who suffer from male factor infertility and complain of hypogonadal symptoms. More studies are needed to further validate CC's efficacy for male infertility and hypogonadism.
Keywords:
Clomiphene citrate (CC); Testosterone; Hypogonadism; Polycythemia; Infertility
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0